II
PTCT icon

Inspire Investing’s PTC Therapeutics PTCT Stock Holding History

Inspire Investing’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$684K Buy
8,382
+823
+11% +$59.4K 0.03% 612
2026
Q1 		$515K Buy
7,559
+1,419
+23% +$100K 0.03% 650
2025
Q4 		$466K Sell
6,140
-1,379
-18% -$100K 0.04% 611
2025
Q3 		$461K Sell
7,519
-424
-5% -$22.1K 0.04% 358
2025
Q2 		$388K Buy
7,943
+1,061
+15% +$50.4K 0.04% 647
2025
Q1 		$351K Sell
6,882
-2,245
-25% -$112K 0.04% 340
2024
Q4 		$412K Sell
9,127
-1,912
-17% -$81.8K 0.05% 354
2024
Q3 		$410K Sell
11,039
-506
-4% -$16.9K 0.04% 721
2024
Q2 		$353K Sell
11,545
-669
-5% -$21.7K 0.04% 486
2024
Q1 		$355K Sell
12,214
-1,833
-13% -$51.3K 0.04% 752
2023
Q4 		$387K Buy
14,047
+267
+2% +$6.11K 0.04% 438
2023
Q3 		$309K Buy
13,780
+74
+0.5% +$2.75K 0.04% 446
2023
Q2 		$557K Buy
+13,706
New +$671K 0.07% 275

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Inspire Investing's PTCT Position: Q2 2026 in Review

Inspire Investing increased its PTC Therapeutics (PTCT) stake by 11% in Q2 2026, buying an estimated $59.4K and bringing the position to 8,382 shares worth $684K. The position accounts for 0.03% of the portfolio, ranked #612.

Inspire Investing first reported a position in PTCT in Q2 2023 and has held it in 13 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Inspire Investing held 8,382 shares of PTC Therapeutics worth $684K as of Q2 2026.
  • Inspire Investing bought 823 PTC Therapeutics shares in Q2 2026, an estimated $59.4K.
  • PTC Therapeutics made up 0.03% of Inspire Investing's portfolio in Q2 2026, its #612 holding.
  • Inspire Investing first reported a position in PTC Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Inspire Investing's 13F filing for Q2 2026, filed 12 Aug 2026.